Study of Evodiamine in Inducing G2/M Phase Arrest in Renal Carcinoma 786-0 Cells and Its Molecular Mechanism
10.13359/j.cnki.gzxbtcm.2015.05.016
- VernacularTitle:吴茱萸碱诱导肾癌786-0细胞G2/M期阻滞及其分子机制
- Author:
Peiyi HE
;
Yanni JIANG
;
Yuhui TAN
;
Biaoyan DU
;
Hongwei SHAO
;
Zhenquan HE
;
Guangxian ZHANG
- Publication Type:Journal Article
- Keywords:
Evodiamine/pharmacology;
Renal carcinoma/TCD therapy;
Cell cycle;
Protein expression;
Cell culture
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2015;(5):853-856
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the growth inhibition effect of evodiamine (Evo) on renal carcinoma 786-0 cells and to explore its molecular mechanism. Methods After treated with Evo, methyl thiazolyl tetrazolium ( MTT) assay was used to detect the vitality of 786-0 cells, flow cytometry was employed to examine the cell cycle distribution in 786-0 cells, and immunoblotting was utilized to determine the expression levels of target proteins related to cell cycle progression. Results Evo remarkably inhibited 786-0 cells vitality in dose-dependent manner. Cell cycle analysis indicated that 786-0 cells were arrested in G2/M phase followed by Evo treatment. Furthermore, the results of immunoblotting showed that Evo up-regulated the protein expression levels of P53, P21 and its downstream target gene CyclinB1 in 786-0 cells. Conclusion Evo treatment can induce 786-0 cell cycle G2/M arrest, and its underlying mechanism might be dependent on the P53/P21 signal pathway.